PHARMING GROUP Stock Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Market Cap | 778M 886M 724M 664M 1.25B 85.34B 1.27B 8.59B 3.36B 41.95B 3.33B 3.25B 145B | P/E 2026 * |
34x | P/E 2027 * | 47.1x |
|---|---|---|---|---|---|
| Enterprise Value | 725M 826M 675M 619M 1.16B 79.54B 1.18B 8.01B 3.13B 39.11B 3.1B 3.03B 135B | EV / Sales 2026 * |
1.8x | EV / Sales 2027 * | 1.58x |
| Free-Float |
97.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 2025-03-03 | |
Kenneth Lynard
DFI | Director of Finance/CFO | 58 | 2025-09-30 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 2020-12-10 |
Mark Pykett
BRD | Director/Board Member | 62 | 2020-12-10 |
| Director/Board Member | 60 | 2021-05-18 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.86% | +1.43% | +47.17% | +161.40% | 1,067B | |
| +1.59% | +4.09% | +56.51% | +52.79% | 635B | |
| +0.95% | +1.91% | +36.30% | +83.13% | 458B | |
| +1.60% | +6.25% | +37.00% | +30.00% | 347B | |
| -0.60% | +1.52% | +36.67% | +39.80% | 295B | |
| -0.14% | +0.60% | +17.29% | +18.19% | 262B | |
| +0.09% | -2.82% | -29.09% | -41.29% | 216B | |
| +1.22% | +2.66% | +22.66% | +59.81% | 203B | |
| -1.18% | -3.70% | +11.28% | +67.43% | 161B | |
| Average | +0.49% | +1.33% | +26.20% | +52.36% | 404.78B | |
| Weighted average by Cap. | +0.76% | +1.95% | +35.99% | +78.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 404M 460M 376M 345M 648M 44.3B 658M 4.46B 1.74B 21.78B 1.73B 1.69B 75.3B | 439M 500M 408M 375M 704M 48.13B 715M 4.85B 1.89B 23.66B 1.88B 1.84B 81.81B |
| Net income | 38.43M 43.75M 35.74M 32.79M 61.62M 4.21B 62.57M 424M 166M 2.07B 164M 161M 7.16B | 35.07M 39.93M 32.61M 29.93M 56.23M 3.85B 57.1M 387M 151M 1.89B 150M 147M 6.54B |
| Net Debt | -52.84M -60.16M -49.14M -45.09M -84.73M -5.79B -86.03M -584M -228M -2.85B -226M -221M -9.85B | -86.38M -98.35M -80.34M -73.72M -139M -9.47B -141M -954M -373M -4.66B -369M -361M -16.1B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
